¼¼°èÀÇ ¼±Ãµ¼º ½ÉÁúȯ(CHD) ½ÃÀå º¸°í¼­(2025³â)
Congenital Heart Disease (CHD) Global Market Report 2025
»óǰÄÚµå : 1703203
¸®¼­Ä¡»ç : The Business Research Company
¹ßÇàÀÏ : On Demand Report
ÆäÀÌÁö Á¤º¸ : ¿µ¹® 200 Pages
 ¶óÀ̼±½º & °¡°Ý (ºÎ°¡¼¼ º°µµ)
US $ 4,490 £Ü 6,371,000
PDF (Single User License) help
PDF º¸°í¼­¸¦ 1¸í¸¸ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμ⠰¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.
US $ 6,490 £Ü 9,209,000
PDF (Site License) help
PDF º¸°í¼­¸¦ µ¿ÀÏ »ç¾÷ÀåÀÇ ¸ðµç ºÐÀÌ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμ⠰¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.
US $ 8,490 £Ü 12,048,000
PDF (Enterprise License) help
PDF º¸°í¼­¸¦ µ¿ÀÏ ±â¾÷ÀÇ ¸ðµç ºÐÀÌ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμ⠰¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.


¤± Add-on °¡´É: °í°´ÀÇ ¿äû¿¡ µû¶ó ÀÏÁ¤ÇÑ ¹üÀ§ ³»¿¡¼­ CustomizationÀÌ °¡´ÉÇÕ´Ï´Ù. ÀÚ¼¼ÇÑ »çÇ×Àº ¹®ÀÇÇØ Áֽñ⠹ٶø´Ï´Ù.
¤± º¸°í¼­¿¡ µû¶ó ÃֽŠÁ¤º¸·Î ¾÷µ¥ÀÌÆ®ÇÏ¿© º¸³»µå¸³´Ï´Ù. ¹è¼Û±âÀÏÀº ¹®ÀÇÇØ Áֽñ⠹ٶø´Ï´Ù.

Çѱ۸ñÂ÷

¼±Ãµ¼º ½ÉÀ庴(CHD) ½ÃÀå ±Ô¸ð´Â ÇâÈÄ ¼ö³â°£ °­·ÂÇÑ ¼ºÀå¼¼¸¦ º¸À̸ç 2029³â±îÁö ¿¬Æò±Õ 9.7%ÀÇ ¿¬Æò±Õ º¹ÇÕ ¼ºÀå·ü(CAGR)·Î 70¾ï 5,000¸¸ ´Þ·¯¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. ¿¹Ãø ±â°£ ÁßÀÇ ¼ºÀåÀº °³¹ßµµ»ó±¹ÀÇ ÀÇ·á ¼­ºñ½º Á¢±Ù¼º È®´ë, ½ÉÀå ¿µ»ó ±â¼úÀÇ Áö¼ÓÀûÀÎ Çõ½Å, Á¶±â ¹ß°ß ¹× Á¶±â Ä¡·á¸¦ À§ÇÑ ÀÎ½Ä Á¦°í Ä·ÆäÀÎ Áõ°¡, Àü ¼¼°è ÀÇ·áºñ Áõ°¡, ¸ÂÃãÇü ÀÇ·áÀÇ ¹ßÀü µî¿¡ ±âÀÎÇÕ´Ï´Ù. ¿¹Ãø ±â°£ Áß ÁÖ¿ä µ¿ÇâÀ¸·Î´Â ÃÖ¼Òħ½À ¼ö¼ú ±â¼úÀÇ Ã¤ÅÃ, ¿ø°Ý ȯÀÚ ¸ð´ÏÅ͸µ ¹× Áø·á¸¦ À§ÇÑ ¿ø°ÝÀÇ·áÀÇ È°¿ë È®´ë, °³ÀÎ ¸ÂÃãÇü Ä¡·á Á¢±Ù¹ý¿¡ ´ëÇÑ ¼ö¿ä Áõ°¡, ±â´É¼º°ú ¼ö¸íÀÌ °­È­µÈ Çõ½ÅÀûÀÎ À̽ÄÇü ÀåºñÀÇ °³¹ß, Áø´Ü ¹× Ä¡·á °úÁ¤¿¡ ÀΰøÁö´É°ú ¸Ó½Å·¯´×ÀÇ ÅëÇÕ µîÀÌ ÀÖ½À´Ï´Ù. µîÀ» µé ¼ö ÀÖ½À´Ï´Ù.

¸ð¼º ´ç´¢º´ÀÇ À¯º´·ü Áõ°¡´Â ÇâÈÄ ¼±Ãµ¼º ½ÉÀ庴(CHD) ½ÃÀå È®´ë¸¦ ÃËÁøÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. Àӽżº ´ç´¢º´(GDM)À¸·Îµµ ¾Ë·ÁÁø ¸ð¼º ´ç´¢º´Àº ÀӽŠÀü ´ç´¢º´ÀÌ ¾ø´ø ¿©¼ºÀÌ ÀӽŠÁß¿¡ ¹ßº´ÇÏ´Â ÁúȯÀÔ´Ï´Ù. ÁÖ·Î ÁÂ½Ä »ýȰ°ú ½Ä½À°üÀÇ º¯È­, °¡Àӱ⠿©¼ºÀÇ ºñ¸¸À² Áõ°¡ µî »ýȰ½À°üÀÇ º¯È­·Î ÀÎÇØ ¹ß»ýÇÕ´Ï´Ù. »ê¸ðÀÇ Ç÷´ç ¼öÄ¡°¡ ³ô¾ÆÁö¸é žÆÀÇ ½ÉÀå ¹ß´ÞÀ» ¹æÇØÇϹǷΠ»ê¸ðÀÇ ´ç´¢º´Àº ¾Æ±âÀÇ ¼±Ãµ¼º ½ÉÀ庴(CHD) À§ÇèÀ» Áõ°¡½Ãų ¼ö ÀÖ½À´Ï´Ù. ³ôÀº Æ÷µµ´ç ¼öÄ¡´Â ¾Æ±âÀÇ Á¤»óÀûÀÎ ½ÉÀå Çü¼º¿¡ ¿µÇâÀ» ¹ÌÃÄ CHDÀÇ °¡´É¼ºÀ» ³ôÀÔ´Ï´Ù. ¿¹¸¦ µé¾î 2023³â 10¿ù ¿µ±¹ Á¤ºÎ ±â°üÀÎ ±¹¸³º¸°Ç¼­ºñ½º(National Health Service)´Â 2Çü ´ç´¢º´ Áø´ÜÀ» ¹ÞÀº ¿©¼ºÀÇ ÀӽŠºÎÀÛ¿ëÀÌ 2021³â 4.9%¿¡¼­ 2022³â 6.6%·Î Áõ°¡Çß´Ù°í º¸°íÇß½À´Ï´Ù. ±× °á°ú, »ê¸ðÀÇ ´ç´¢º´ ȯÀÚ ¼ö Áõ°¡°¡ ¼±Ãµ¼º ½ÉÀ庴(CHD) ½ÃÀå ¼ºÀå¿¡ ±â¿©Çϰí ÀÖ½À´Ï´Ù.

¼±Ãµ¼º ½ÉÀåÁúȯ ½ÃÀåÀÇ ÁÖ¿ä ±â¾÷Àº ȯÀÚÀÇ ¿¹ÈÄ¿Í »îÀÇ ÁúÀ» Çâ»ó½Ã۱â À§ÇØ ºñ¼ö¼úÀû ½ÉÀåÆÇ¸·ÀÇ ±â¼ú Çõ½ÅÀ» ÃßÁøÇϰí ÀÖ½À´Ï´Ù. ºñ¼ö¼úÀû ½ÉÀåÆÇ¸·Àº °æÇÇÀû Ä«Å×ÅͶó°íµµ ºÒ¸®¸ç, ±âÁ¸ÀÇ °³½É¼ú ¾øÀÌ ½ÉÀåÆÇ¸·ÁõÀ» Ä¡·áÇÏ´Â ÀÇ·á±â±âÀÔ´Ï´Ù. ¿¹¸¦ µé¾î 2023³â 2¿ù ¹Ì±¹ÀÇ ÀÇ·á ±â¼ú ±â¾÷ ¸ÞµåÆ®·Î´Ð(Medtronic)Àº Harmony Transcatheter Pulmonary Valve(TPV) ½Ã½ºÅÛÀ» ÀçÃâ½ÃÇß½À´Ï´Ù. °³½É¼úÀ» ´ëüÇÒ ¼ö ÀÖ´Â ÃÖ¼Ò Ä§½ÀÀûÀÎ ÀÌ ½Ã½ºÅÛÀº ¼±Ãµ¼º ½ÉÀåÁúȯ, ƯÈ÷ ¼±Ãµ¼º ¶Ç´Â ¼ö¼ú·Î ±³Á¤µÈ ¿ì½É½Ç À¯Ãâ·Î(RVOT) ÀÌ»óÀ» °¡Áø ȯÀÚµéÀ» À§ÇÑ °ÍÀÔ´Ï´Ù. ÀÌ ¹ëºê´Â ¿À¸¥ÂÊÀ¸·Î ¼³°èµÈ ÃÖÃÊÀÇ FDA ½ÂÀÎ ¹ëºêÀ̸ç, ÁßÁõ Æóµ¿¸Æ ÆÇ¸· ¿ª·ù ȯÀÚ¿¡°Ô ºñ¼ö¼úÀû ¼Ö·ç¼ÇÀ» Á¦°øÇÕ´Ï´Ù. Harmony TPV ½Ã½ºÅÛÀº 2021³â ¹Ì±¹ FDAÀÇ ½ÂÀÎÀ» ¹Þ¾Æ ÀÚ¹ßÀû ȸ¼ö ÈÄ ÀçÆÇ¸ÅµÉ ¿¹Á¤À̸ç, ÀÌ´Â ¼±Ãµ¼º ½ÉÀ庴 ȯÀÚ¸¦ À§ÇÑ ¼Ö·ç¼ÇÀ» ¹ßÀü½Ã۱â À§ÇÑ ¸ÞµåÆ®·Î´ÐÀÇ Çå½ÅÀ» °­Á¶ÇÕ´Ï´Ù.

¸ñÂ÷

Á¦1Àå °³¿ä

Á¦2Àå ½ÃÀåÀÇ Æ¯Â¡

Á¦3Àå ½ÃÀå µ¿Çâ°ú Àü·«

Á¦4Àå ½ÃÀå - ±Ý¸®, ÀÎÇ÷¹À̼Ç, ÁöÁ¤ÇÐ, ½ÅÇü Äڷγª¹ÙÀÌ·¯½º ¹× °æ±âȸº¹ÀÌ ½ÃÀå¿¡ ¹ÌÄ¡´Â ¿µÇâÀ» Æ÷ÇÔÇÑ °Å½Ã°æÁ¦ ½Ã³ª¸®¿À

Á¦5Àå ¼¼°èÀÇ ¼ºÀå ºÐ¼®°ú Àü·« ºÐ¼® ÇÁ·¹ÀÓ¿öÅ©

Á¦6Àå ½ÃÀå ¼¼ºÐÈ­

Á¦7Àå Áö¿ªº°¡¤±¹°¡º° ºÐ¼®

Á¦8Àå ¾Æ½Ã¾ÆÅÂÆò¾ç ½ÃÀå

Á¦9Àå Áß±¹ ½ÃÀå

Á¦10Àå Àεµ ½ÃÀå

Á¦11Àå ÀϺ» ½ÃÀå

Á¦12Àå È£ÁÖ ½ÃÀå

Á¦13Àå Àεµ³×½Ã¾Æ ½ÃÀå

Á¦14Àå Çѱ¹ ½ÃÀå

Á¦15Àå ¼­À¯·´ ½ÃÀå

Á¦16Àå ¿µ±¹ ½ÃÀå

Á¦17Àå µ¶ÀÏ ½ÃÀå

Á¦18Àå ÇÁ¶û½º ½ÃÀå

Á¦19Àå ÀÌÅ»¸®¾Æ ½ÃÀå

Á¦20Àå ½ºÆäÀÎ ½ÃÀå

Á¦21Àå µ¿À¯·´ ½ÃÀå

Á¦22Àå ·¯½Ã¾Æ ½ÃÀå

Á¦23Àå ºÏ¹Ì ½ÃÀå

Á¦24Àå ¹Ì±¹ ½ÃÀå

Á¦25Àå ij³ª´Ù ½ÃÀå

Á¦26Àå ³²¹Ì ½ÃÀå

Á¦27Àå ºê¶óÁú ½ÃÀå

Á¦28Àå Áßµ¿ ½ÃÀå

Á¦29Àå ¾ÆÇÁ¸®Ä« ½ÃÀå

Á¦30Àå °æÀï ±¸µµ¿Í ±â¾÷ °³¿ä

Á¦31Àå ±âŸ ´ë±â¾÷°ú Çõ½ÅÀû ±â¾÷

Á¦32Àå ¼¼°èÀÇ ½ÃÀå °æÀï º¥Ä¡¸¶Å·°ú ´ë½Ãº¸µå

Á¦33Àå ÁÖ¿ä ÇÕº´°ú Àμö

Á¦34Àå ÃÖ±Ù ½ÃÀå µ¿Çâ

Á¦35Àå ½ÃÀåÀÇ ÀáÀç·ÂÀÌ ³ôÀº ±¹°¡, ºÎ¹®, Àü·«

Á¦36Àå ºÎ·Ï

KSA
¿µ¹® ¸ñÂ÷

¿µ¹®¸ñÂ÷

Congenital heart disease (CHD) encompasses a spectrum of birth defects affecting the structure and function of the heart present at birth. These defects may involve abnormalities in the heart walls, valves, arteries, and veins near the heart. Treatment for CHD varies depending on the type and severity of the defect and may include medications, catheter-based interventions, open-heart surgery, or heart transplantation.

The primary types of congenital heart disease (CHD) include heart valve defects, heart wall defects, blood vessel defects, and others. Heart valve defects entail abnormalities or malfunctions in the heart valves, which regulate blood flow within the heart. Diagnosis methods may include electrocardiograms, chest X-rays, echocardiograms, transesophageal echocardiograms, pulse oximetry, exercise stress tests, cardiac computed tomography (CT) scans, magnetic resonance imaging (MRI), cardiac catheterization, among others. Treatment options range from interventional cardiology procedures to cardiac surgery, medication management, telemedicine, and lifestyle modifications. CHD affects individuals across all age groups, including infants, children, adolescents, and adults, who receive treatment in hospitals, clinics, diagnostic centers, ambulatory surgical centers, and research and academic institutions.

The congenital heart disease market research report is one of a series of new reports from The Business Research Company that provides congenital heart disease market statistics, including congenital heart disease industry global market size, regional shares, competitors with a congenital heart disease market share, detailed congenital heart disease market segments, market trends and opportunities, and any further data you may need to thrive in the congenital heart disease industry. This congenital heart disease market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The congenital heart disease (CHD) market size has grown rapidly in recent years. It will grow from $4.42 billion in 2024 to $4.87 billion in 2025 at a compound annual growth rate (CAGR) of 10.1%. The growth in the historic period can be attributed to the increased prevalence of risk factors such as obesity and smoking, improved diagnostic technologies, expanded geriatric population, heightened awareness campaigns, enhanced reimbursement policies, and increased investment in research and development.

The congenital heart disease (CHD) market size is expected to see strong growth in the next few years. It will grow to $7.05 billion in 2029 at a compound annual growth rate (CAGR) of 9.7%. The growth in the forecast period can be attributed to expanding access to healthcare services in developing regions, continuous innovation in cardiac imaging technologies, growing awareness campaigns promoting early detection and treatment, rising healthcare expenditure globally, and the development of personalized medicine. Major trends in the forecast period include adoption of minimally invasive surgical techniques, expanding use of telemedicine for remote patient monitoring and consultations, rising demand for personalized treatment approaches, development of innovative implantable devices with enhanced functionality and longevity, integration of artificial intelligence and machine learning in diagnostic and therapeutic processes.

The growing prevalence of maternal diabetes is expected to drive the expansion of the congenital heart disease (CHD) market in the future. Maternal diabetes, also known as gestational diabetes mellitus (GDM), develops during pregnancy in women who did not have diabetes before conceiving. It is primarily caused by lifestyle changes, such as sedentary behavior, poor dietary habits, and rising obesity rates among women of childbearing age. Maternal diabetes can increase the risk of congenital heart disease (CHD) in infants, as elevated blood sugar levels in the mother can disrupt fetal heart development. The high glucose levels affect the normal formation of the baby's heart, leading to a higher likelihood of CHD. For example, in October 2023, the National Health Service, a UK government agency, reported that adverse pregnancy outcomes for women diagnosed with type 2 diabetes increased from 4.9% in 2021 to 6.6% in 2022. As a result, the rising number of maternal diabetes cases is contributing to the growth of the congenital heart disease (CHD) market.

Key players in the congenital heart disease market are innovating non-surgical heart valves to enhance patient outcomes and quality of life. Non-surgical heart valves, also known as transcatheters, are medical devices treating heart valve diseases without conventional open-heart surgery. For instance, in February 2023, Medtronic, a US-based medical technology company, reintroduced its Harmony Transcatheter Pulmonary Valve (TPV) System. This system, a minimally invasive alternative to open-heart surgery, addresses patients with congenital heart disease, particularly those with native or surgically repaired right ventricular outflow tract (RVOT) anomalies. It stands as the first FDA-approved valve designed for the right side, offering a non-surgical solution for severe pulmonary valve regurgitation patients. The Harmony TPV System received U.S. FDA approval in 2021 and was reintroduced following a voluntary recall, underscoring Medtronic's dedication to advancing solutions for congenital heart disease patients.

In May 2024, Novartis Healthcare Private Limited, a Switzerland-based pharmaceutical company, partnered with Ayala Healthcare Holdings, Inc. (AC Health) to launch an Integrated Cardiovascular and Cancer Care initiative. This collaboration aims to expand access to innovative treatments for breast cancer, heart failure, and high cholesterol. Ayala Healthcare Holdings, Inc. (AC Health) is a Philippines-based pharmaceutical company specializing in generic drugs.

Major companies operating in the congenital heart disease (CHD) market are Pfizer Inc., AstraZeneca Plc, Abbott Laboratories, Novartis AG, Medtronic, Siemens Healthineers, Philips Healthcare, Roche Diagnostics International Ltd., Boston Scientific Corp., Laboratory Corporation of America Holdings (LabCorp), Terumo Corporation, Mindray Medical International Limited, Canon Medical Systems Corporation, Masimo Corporation, Neusoft Corp., Carestream Health, Midmark Corporation, Contec Medical Systems, Randox Laboratories Ltd., Schiller AG, BPL Medical Technologies, Compumedics Limited, Biocare Medical, Bionet America Inc., Nasan Medical Electronics Pvt Ltd

North America was the largest region in the congenital heart disease (CHD) market in 2024. The regions covered in the congenital heart disease (CHD) market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in the congenital heart disease (CHD) market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The congenital heart disease (CHD) market consists of revenues earned by entities by providing services such as medical consultations, diagnostic tests, and support services. The market value includes the value of related goods sold by the service provider or included within the service offering. The congenital heart disease (CHD) market also includes sales of cardiac implants such as pacemakers, implantable cardioverter-defibrillators (ICDs), and ventricular assist devices (VADs). Values in this market are 'factory gate' values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Congenital Heart Disease (CHD) Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on congenital heart disease (chd) market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

Where is the largest and fastest growing market for congenital heart disease (chd) ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The congenital heart disease (chd) market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

Scope

Table of Contents

1. Executive Summary

2. Congenital Heart Disease (CHD) Market Characteristics

3. Congenital Heart Disease (CHD) Market Trends And Strategies

4. Congenital Heart Disease (CHD) Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Covid And Recovery On The Market

5. Global Congenital Heart Disease (CHD) Growth Analysis And Strategic Analysis Framework

6. Congenital Heart Disease (CHD) Market Segmentation

7. Congenital Heart Disease (CHD) Market Regional And Country Analysis

8. Asia-Pacific Congenital Heart Disease (CHD) Market

9. China Congenital Heart Disease (CHD) Market

10. India Congenital Heart Disease (CHD) Market

11. Japan Congenital Heart Disease (CHD) Market

12. Australia Congenital Heart Disease (CHD) Market

13. Indonesia Congenital Heart Disease (CHD) Market

14. South Korea Congenital Heart Disease (CHD) Market

15. Western Europe Congenital Heart Disease (CHD) Market

16. UK Congenital Heart Disease (CHD) Market

17. Germany Congenital Heart Disease (CHD) Market

18. France Congenital Heart Disease (CHD) Market

19. Italy Congenital Heart Disease (CHD) Market

20. Spain Congenital Heart Disease (CHD) Market

21. Eastern Europe Congenital Heart Disease (CHD) Market

22. Russia Congenital Heart Disease (CHD) Market

23. North America Congenital Heart Disease (CHD) Market

24. USA Congenital Heart Disease (CHD) Market

25. Canada Congenital Heart Disease (CHD) Market

26. South America Congenital Heart Disease (CHD) Market

27. Brazil Congenital Heart Disease (CHD) Market

28. Middle East Congenital Heart Disease (CHD) Market

29. Africa Congenital Heart Disease (CHD) Market

30. Congenital Heart Disease (CHD) Market Competitive Landscape And Company Profiles

31. Congenital Heart Disease (CHD) Market Other Major And Innovative Companies

32. Global Congenital Heart Disease (CHD) Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Congenital Heart Disease (CHD) Market

34. Recent Developments In The Congenital Heart Disease (CHD) Market

35. Congenital Heart Disease (CHD) Market High Potential Countries, Segments and Strategies

36. Appendix

(ÁÖ)±Û·Î¹úÀÎÆ÷¸ÞÀÌ¼Ç 02-2025-2992 kr-info@giikorea.co.kr
¨Ï Copyright Global Information, Inc. All rights reserved.
PC¹öÀü º¸±â